ReShape Lifesciences Debt to Equity

As of the most recent data, RSLS shows a debt-to-equity ratio of 0.01. That is below the Healthcare sector average of 0.31. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.31. ReShape Lifesciences is at 0.01, which is lower that average. That is roughly 98.1% below the sector mean. Use the comparison chart on this page to see how RSLS stacks up against individual peers as well.

Investors watch RSLS's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. ReShape Lifesciences's latest reading is 0.01. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has ReShape Lifesciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently 0.01) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.31, while RSLS is at 0.01. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.